Manipal Hospital Doctors give new lease of life to 47-Year-old Iraqi Patient with HIPEC surgery

Dwarka: Contrary to the common misconception that ‘Stage IV cancer patients cannot be treated’, doctors at Manipal Hospital, Dwarka have successfully saved life of a 47-year-old male from Basra, Iraq, who was diagnosed with stage 4 rectal cancer. 

The patient had initially been diagnosed with piles and was undergoing treatment for the same in his country. However, it was later discovered that he was suffering from rectal cancer that had been misdiagnosed earlier. The patient underwent multiple chemotherapy and radiation sessions, post which he was referred to Dr Sanjeev Kumar, Surgical Oncologist, Manipal Hospital in Dwarka.

Also Read:Manipal Hospital doctors give new lease of life to 17-year-old tiger attack survivor after multiple reconstructive surgeries

After evaluation, he was found to have Peritoneal disease in addition to the Rectal Cancer (Stage IV). Given the complexity of the case, Dr Sanjeev Kumar and his team decided to undertake a major surgery, performing CRS (Cytoreductive Surgery) and HIPEC (Hyperthermic Intraperitoneal Chemotherapy Surgery). These procedures were combined with the surgical removal of the cancerous tumour and the administration of heated chemotherapy to the abdomen, to maximize the effectiveness of the treatment.

Usually, stage IV cancers are incurable. But, peritoneal cancers, disease which spread to abdominal wall lining and surface, can be treated. CRS and HIPEC is a highly complex and challenging procedure. In HIPEC, heated mixture of chemotherapy is added in the operation field.

Commenting on the case, Dr Sanjeev Kumar, Consultant- Surgical Oncology, Manipal Hospital, Dwarka said, “This was challenging case as the patient had previously been misdiagnosed, and the fact that he weighed 122 kg added an additional level of complexity to the treatment. However, after thorough evaluation, we opted for a comprehensive treatment approach that combined advanced techniques (HIPEC).

Despite an unfavorable initial prognosis, the patient was successfully treated under the guidance of our team and returned home with a better quality of life. The success of his treatment highlights the importance of advanced medical solutions to complex problems like cancer.”

Also Read:Manipal Hospital in association with IAP organises Health Camp for Children with Down Syndrome

Powered by WPeMatico

Appoint only MBBS Degree Holders As Duty Medical Officers: Telangana Medical Council directs all hospitals

Hyderabad: The Telangana State Medical Council (TSMC) has issued directions to all the Super Speciality Hospitals, Nursing Homes, Clinics, Private Hospitals and Registered Medical Practitioners in the State to only appoint MBBS degree holders as Duty Medical Officers (DMOs). 

Issuing a Circular in this regard on 10.04.2024, the council has also issued strict instructions not to appoint other degree holders such as Pharm D, BAMS, BHMS, BUMS, etc as DMOs. The Council has also asked all the consultants practising in the State to get registered with TSMC and renew their registration in time.

Such directions were issued by the Council after it inspected various hospitals and clinics in the Greater Hyderabad Municipal Corporation (GHMC) area and found several lapses and violations of rules.

The Council noted that most of the hospitals were not displaying the registration numbers issued by medical council against the names of the consultant doctors in the hospital display board.

Further, it found that some of the hospitals were appointing Pharm D degree holders as Duty Medical Officers, and such officers were also tasked to write the case sheets of the patients.

Apart from this, the Council also came to know that many hospitals were appointing AYUSH doctors as DMOs, and few of the consultants from other States were practicing in Telangana without registering in TSMC. Some of the Consultants were found to be practicing without the renewal of registration with TSMC.

Also Read: Telangana Medical Council Continues Battle Against Quackery: 2 more FIRs Filed Against Unqualified Practitioners

Taking note of the situation, TSMC ordered in its latest circular, “In this connection, the Telangana State Medical Council is directing all the Super Speciality Hospitals, Nursing Homes, Clinics, Private Hospitals and also the Registered Medical Practitioners in the State to appoint only MBBS degree holders as DMO’s. The TSMC strictly instruct not to appoint other degree holders like Pharm D, BAMS, BHMS, BUMS etc., as Duty Medical Officers and also see that all consultants who are practicing in Telangana State should get registered/renewed in TSMC.”

Meanwhile, the Council has also advised the patients to verify the genuineness of the doctors online by using the Doctor Search option.

“It is further instructed that while appointing the doctors, the appointing authority may verify the genuinity of the doctors with the consultation of TSMC, you can also verify through online by using Doctor Search option,” the Circular stated.

“If any violations occurred, the TSMC will take appropriate action as per TSMRP Act and NMC Act 2019,” the Council further clarified.

Earlier this year, Telangana Government authorities issued an ultimatum to the medical establishments in the State and asked them to ensure that they have proper registration. The authorities asked them to register or renew their registration at the earliest in case they lacked the requirement. The health facilities were warned of action under the Clinical Establishments Act if they failed to adhere to these instructions.

Meanwhile, aiming to eradicate quackery in the State, TSMC has been filing several FIRs against quacks engaging in the practice of modern medicine and prescribing scheduled drugs.

Earlier, the Council had also complained to the Ayush Board to take necessary action against the following doctors who possess only BAMS, BHMS & BUMS degrees but are illegally practicing Allopathic Medicine without MBBS Qualification.

Also Read: Register or face action: Medical Establishments in Telangana Get Ultimatum

Powered by WPeMatico

INI CET July 2024 At NIMHANS, SCTIMST: Check seat matrix, fee details here

New Delhi- On its website, the AIIMS has released prospectus for INI CET July 2024 admissions at National Institute of Mental Health and Neuro Sciences (NIMHANS) and Shree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST).

In the 2  prospectus, the institutes have provided details on the fees, eligibility criteria, seat matrix and much more. The candidates can check out the same as mentioned below.

Also Read: AIIMS INI CET July 2024 registrations begin, Apply Now
NIMHANS

ELIGIBILITY CRITERIA OF (NIMHANS) FOR MD, DM (3 & 6 YEARS), MCh (3 & 6 YEARS) COURSES

1 MBBS degree from a recognised University or from any other University recognised as equivalent thereto by NIMHANS and by the Medical Council of India/ National Medical Commission (NMC).

2 The candidate should have completed a compulsory rotation internship of one year after MBBS or its equivalent as recognized by NMC on or before 31st July 2024. A certificate to that effect has to be produced. The candidate should have permanent/provisional registration with the State Medical Council. Candidates who do not submit the Internship certificate on the day of admission to the course will not be admitted under any circumstance.

Also Read: INI CET July 2024 at JIPMER: 146 seats available for MD, MS, MCh, MDS candidates

FEES STRUCTURE

S.NO

DETAILS

AMOUNT PER YEAR

COURSE WITH DURATION IN YEARS

MD Course

DM/M.Ch Courses

3 Years

6 Years

1

Eligibility fee

5,000

500

500

500

100

2

Registration fee

1,000

1,000

1,000

3

Tuition Fee

50,000

50,000

50,000

4

Laboratory fee

500

1,500

3,000

5

Gymkhana & Recreation Fee

250

750

1,500

6

Library fee

1,000

3,000

6,000

7

Caution Money & Hostel Deposit

5,000

5,000

5,000

8

Identification card fee

100

100

100

9

NHS card fee

100

100

100

10

Examination fee: Part I

4,500

4,500

4,500

11

Part II

6,500

6,500

6,500

12

Part III

12,500

12,500

13

Exit Examination Application fee

50

100

150

14

Marks Card fee

100

200

100

15

Total

73,250

90,950

FOREIGN NATIONALS (EXCEPT FROM SAARC COUNTRIES)

S.NO

NAME OF THE COURSE

TUITION FEE

REGISTRATION FEE

1

DM/M.Ch. ( 6 years duration) Courses

60,000

1,000

2

MD ( 3 years duration) Courses

50,000

1,000

SEAT MATRIX

The following seats are reserved for various ‘Domicile Categories’ in various courses:

Domicile reservation category

Karnataka Domicile

North Eastern States Domicile

MD in Psychiatry Course:

Session 1

04 seats under ‘Institute Stipendiary’ and 01 seat under ‘Sponsored Category’

03 Seats under ‘Institute Stipendiary Category’

SCTIMST

IMPORTANT DATES FOR ADMISSION IN (SCTIMST)

Admission Notification

As per schedule/important dates available in the Prospectus Part-A of the INIs for July 2024 session

Availability of online Application

Hall ticket download

Commencement of courses

1st July 2024

Director’s welcome address

06th July 2024

ELIGIBILITY CRITERIA OF (SCTIMST) FOR MD, MS, DM (6 YEARS), MCh (6 YEARS) & MDS COURSES

MBBS or equivalent degree from a recognised university. They should complete one year of compulsory internship from a medical college/institute on or before 31st July 2024. The candidate should have applied for and obtained registration with the State Medical Council before admission.

Also Read: AIIMS INI CET July 2024: Know Eligibility Criteria, complete schedule, All Details Here

FEES STRUCTURE

S.NO

PARTICULARS

AMOUNT (INR)

1

Admission fee

2,000

2

Tuition Fee

63,000 (per year)

3

Caution Deposit (Refundable)

10,000

4

Examination Fee

10,000

5

Thesis Evaluation Fee

1500

6

Identity Card

220

7

Library

1,000

8

Student Welfare Fund

1,000

9

Certificates

1,000

10

Miscellaneous Fee

10,000

SEAT MATRIX

Program

Number of Seats

Duration (Years)

Qualifications required

General quota

Sponsored seats

MD in Transfusion Medicine

NIL

1

3

MBBS or equivalent degree from a recognised University

To view the (SCTIMST) prospectus, click the link below

https://medicaldialogues.in/pdf_upload/sctimst-trivandrum-prospectus-236015.pdf

To view the (NIMHANS) prospectus, click the link below

https://medicaldialogues.in/pdf_upload/nimhans-prospectus-236014.pdf

Powered by WPeMatico

Choosing sugary drinks over fruit juice for toddlers may increase risk of adult obesity: Study

Consuming sugar-sweetened drinks in the first few years of childhood can be linked to poor diet patterns that increase the risk of obesity in later life, according to a new study by the School of Psychology at Swansea University.

Published in the European Journal of Clinical Nutrition, the study tracked the influence of diet on 14,000 British children from birth to adulthood and is believed to be the longest of its kind ever reported.

Using the Avon Longitudinal Study of Parents and Children, the research team found:

Children who drank fizzy drinks such as cola or sugar-sweetened fruit cordials before the age of two gained more weight when they were 24 years old. Girls who had pure fruit juice gained less weight, while the weight of boys remained the same.

At three years of age, toddlers who drank cola consumed more calories, fat, protein, and sugar but less fibre. In contrast, those given pure apple juice consumed less fat and sugar but higher amounts of fibre.

The study also highlighted corresponding differences in food choices. Children who consumed pure apple juice often followed a diet with more fish, fruit, green vegetables, and salad, whereas those drinking cola ate more burgers, sausages, pizza, french fries, meat, chocolate, and sweets.

Additionally, the team discovered a link between sugar-sweetened drinks and social deprivation, with children from affluent backgrounds more likely to have access to pure fruit juice.

Lead researcher Professor David Benton said: “The early diet establishes a food pattern that influences, throughout life, whether weight increases. The important challenge is to ensure that a child develops a good dietary habit: one that offers less fat and sugar, although pure fruit juice, one of your five a day, adds vitamin C, potassium, folate, and plant polyphenols.”

Dr Hayley Young added: “Obesity is a serious health concern, one that increases the risk of many other conditions. Our study shows that the dietary causes of adult obesity begin in early childhood and that if we are to control it, more attention needs to be given to our diet in the first years of life.”

References: Benton, D., Young, H.A. Early exposure to sugar sweetened beverages or fruit juice differentially influences adult adiposity. Eur J Clin Nutr (2024). https://doi.org/10.1038/s41430-024-01430-y

Powered by WPeMatico

Submit analysis of clinical data of Asian, Indian Population: CDSCO Panel Tells AstraZeneca on Durvalumab

New Delhi: In response to the drug major AstraZeneca’s proposal for the approval of additional indication of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined the firm to submit the subset analysis of the clinical data of Asian population and Indian population of Global clinical study(AEGEAN) conducted in the proposed indication.

In addition to the above, the expert panel stated to submit the results of the ongoing Phase IV clinical study and the status of regulatory approval of the proposed indication of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution.

This came after the drug major AstraZeneca presented the proposal for approval of additional indication i.e.,“Durvalumab (IMFINZI) in combination with chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy after surgery, is indicated for the treatment of patients with resectable (tumours ≥ 4 cm and/or node positive) NSCLC and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements” based on the global clinical trial conducted including subjects from India.

Durvalumab injection is in a class of medications called monoclonal antibodies. It works by helping the immune system to slow or stop the growth of cancer cells. Durvalumab is an anticancer antibody that works to promote the antitumor responses mediated by immune cells. By blocking the action of PD-L1, durvalumab exerts its anticancer effects by increasing T-cell activation and enhancing the detection and ablation of tumor cells.

Durvalumab is used alone or with other drugs to treat adults with certain types of biliary tract cancer (including bile duct cancer and gallbladder cancer), hepatocellular carcinoma (a type of liver cancer), non-small cell lung cancer, and small cell lung cancer.

At the recent SEC meeting for Oncology held on 19th and 20th March 2024, the expert panel reviewed the proposal presented by the drug major AstraZeneca for the approval of the additional indication of Durvalumab (IMFINZI) based on the global clinical trial conducted including subjects from India.

The committee noted that the proposed indication is not yet approved by any regulatory authorities. Furthermore, the expert panel found that phase IV study of the drug is ongoing in India for the approved indication i.e., locally advanced, unresectable non-small cell lung cancer (NSCLC) and urothelial cancer.

After detailed deliberation, the committee recommended the firm to submit

1)subset analysis of clinical data of the Asian population and Indian population of Global clinical study(AEGEAN) conducted in the proposed indication.

2) Results of ongoing Phase IV clinical study

3) Status of regulatory approval of the proposed indication for further evaluation.

Also Read:Eli Lilly Gets CDSCO Panel Nod To Market Mirikizumab for ulcerative colitis in adults

Powered by WPeMatico

Lupin Gets CDSCO Panel Nod to Study Glycopyrronium Bromide, Vilanterol Trifenatate powder for inhalation in capsule

New Delhi: Reviewing the Phase IV clinical trial protocol of Lupin’s pulmonary FDC (Fixed Dose Combination) Glycopyrronium Bromide plus Vilanterol Trifenatate powder for inhalation in capsule, the Subject Expert Committee (SEC) functioning under the Central Drugs Standard Control Organization (CDSCO) has approved the firm conduct the Phase IV clinical trial of the said combination.

This decision came after the firm presented the Phase IV clinical trial protocol before the committee.

Glycopyrronium is an anticholinergic agent used to treat hyperhidrosis, severe drooling, and COPD, as well as in combination with other medications for ulcer treatment and anesthesia.

Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD.

During the recent SEC meeting for Pulmonary held on March 5th, 2024, the expert panel reviewed the Phase IV clinical trial protocol of the pulmonary FDC Glycopyrronium Bromide eq. to 50mcg Glycopyrronium 63mcg + Vilanterol Trifenatate eq. to 25mcg Vilanterol 40mcg powder for inhalation in capsule.

After detailed deliberation, the committee recommended the conduct of the Phase IV clinical trial. Furthermore, the expert panel suggested that the firm is required to submit the Phase IV clinical trial report to CDSCO for further review by the committee.”

Also Read: CT waiver not considered, Conduct BA study: CDSCO Panel Tells Sun Pharma on Pulmonary FDC

Powered by WPeMatico

NMC specifies how many leaves medico can take while pursuing PG medical courses

The National Medical Commission (NMC) has recently specified how many leaves a medico can take while pursuing PG medical courses.

According to a recent NMC notification, PG medical students are allowed “weekly one-day off (subject to exigencies of work). In addition, they are eligible for twenty days of Paid Casual Leave. Five days of Academic Leave per year, if availed by a student will be counted as duty. Thus, a student is entitled to 52 weekly offs and 20 Paid Casual Leave per year.”
For more information, click on the link below:

Powered by WPeMatico

Health Bulletin 13/ April/ 2024

Here are the top medical news for the day:

Delhi government’s outdated essential medicines list has more drugs than national, WHO lists
The Essential Medicine List (EML) managed by the Delhi government comprises 806 drugs and 1,520 formulations, a figure comparable to the World Health Organisation’s list. However, it hasn’t been updated since 2016, leading to concerns over medicine shortages in government facilities. 

Delhi boy swallows ₹5-coin, doctor’s timely intervention saves his life

Amidst the hustle and bustle of Delhi’s Moolchand Hospital, a young boy’s life hung in the balance after he accidentally swallowed a five-rupee coin. Shubham Mishra, son of Umashankar Mishra, found himself in a precarious situation when the coin lodged itself in his throat, posing a potentially fatal risk. Despite the absence of symptoms, an X-ray revealed the alarming truth: a currency coin lay nestled within his stomach.

Swift action was imperative, and Dr. Rishi Raman, leading a dedicated team at Moolchand Hospital, stepped up to the challenge. With precision and expertise, they administered anesthesia and performed the delicate Roth net procedure to extract the coin, averting a tragedy that loomed dangerously close.
How to appoint HoDs in Central Govt hospitals, associated medical colleges?
The Union Ministry of Health and Family Welfare has recently notified the latest guidelines for appointing the Head of the Departments (HoDs) in three Central Government Hospitals and associated medical colleges.

Releasing an Office Memorandum (OM) on 28.03.2024, the Ministry notified about the rules regarding the composition of the Standing Selection Committee, and the tenure of the said Committee. Apart from this, the latest guidelines also include details about the process of selecting HoDs, eligibility criteria for applying to the posts of HoDs, qualifications and experience required to be eligible to apply, details of how to apply, selection of a panel of candidates by the committee, details of the panel, eligibility for consideration by the selection committee etc.

For more information, click on the link below:

Powered by WPeMatico

Kenya drug regulator recalls a batch of JnJ children cough syrup

Nairobi: Kenya’s drug regulator said on thursday it is recalling a batch of Johnson & Johnson children’s cough syrup, following Nigeria’s recall of the same batch of medication under the Benylin Paediatric brand.

Nigeria’s health regulator revealed that laboratory tests conducted on the syrup indicated a concerning level of diethylene glycol. This chemical has been associated with the deaths of numerous children in countries including Gambia, Uzbekistan, and Cameroon since 2022, marking one of the most severe episodes of poisoning linked to oral medication worldwide.

According to a Reuters report, the Pharmacy and Poisons Board (PPB) of Kenya stated in a statement that it had initiated investigations into the matter and recommended the suspension of sales for certain batches of the product, urging their return to suppliers.

Kenvue, the entity now in possession of the Benylin brand following its separation from J&J last year, responded by stating its engagement with Nigeria’s health regulator and undertaking its own evaluation to authenticate the sampled product, assess testing procedures, and review results.

“We take this matter very seriously and are acting with urgency to conduct a thorough safety and quality assessment,” Kenvue said in a statement.

The batch under recall, manufactured by J&J in South Africa in May 2021 and bearing an expiration date of April 2024, was identified by the PPB as the subject of concern.

Read also: USFDA approves Carvykti for patients with Relapsed or Refractory Multiple Myeloma who have received at least one prior line of therapy

Powered by WPeMatico

Pune Cardiologist Dr Manuel Durairaj passes away

Pune: Dr Manuel Durairaj, an illustrious figure in the realm of cardiology, breathed his last, leaving behind an indelible legacy of excellence in clinical practice, research and academia. Throughout his illustrious career, Dr Durairaj earned global acclaim for his profound expertise and unwavering dedication to advancing the field of cardiology.

A distinguished alumnus of Armed Forces Medical College, Dr Durairaj a Gold Medalist, completed his DM Cardiology in 1974 at CMC Vellore. Following his academic pursuits, he embarked on a remarkable journey in the Army Medical Corp, retiring with the esteemed rank of Lieutenant Colonel. His tenure in the armed forces was marked by exemplary service and a commitment to upholding the highest standards of medical care.  

Also Read:Pune: 23 private hospitals get show cause notice for violation of Nursing Home Act

According to Pune Mirror, Dr Durairaj’s professional journey took him to prestigious institutions, including CMC Vellore and Poona University, where he played a pivotal role in establishing the DM Cardiology programme. His visionary leadership as Head of Cardiology at MH (CTC), Lullanagar, laid the foundation for groundbreaking advancements in cardiac care. In 1988, Dr Durairaj embarked on a new chapter in his career by founding the Marian Cardiac Centre and Research Foundation, a beacon of hope for countless individuals grappling with cardiac ailments.

His tenure as Professor and inaugural Chairman of the Academic Department of Cardiology at the Grant Medical Foundation in Pune exemplified his unwavering commitment to nurturing the next generation of medical professionals.

A luminary in his field, Dr Durairaj’s influence extended far beyond the realms of academia and clinical practice. His transformative work in cardiology revolutionized treatment modalities, saving countless lives and setting new benchmarks for excellence in healthcare delivery. His compassionate approach endeared him to patients from diverse corners of the globe, with many seeking his expertise from the Middle East, United States, West Indies, West Africa, and beyond.

Beyond his professional achievements, Dr Durairaj’s altruistic spirit and unwavering commitment to serving humanity were evident in his tireless efforts to provide care and support to the less fortunate. Dr Durairaj’s passing leaves a void in the medical fraternity, but his legacy of compassion, dedication, and excellence will continue to inspire generations to come. He is survived by his beloved wife, Mrs Valsamma, children Mrs Manju Durairaj Schwister and Dr Manoj Durairaj, along with grandchildren Joseph-Durai, James, and Maria.

A solemn church service will be held on April 12 at 4:30 pm at St. Patrick’s Cathedral, Pune, Prince of Wales Drive, followed by interment at Sepulchre Cemetery, Hadapsar. As the medical community mourns the loss of a stalwart, Dr Manuel Durairaj’s enduring impact on healthcare and humanity will be cherished and commemorated by all whose lives he touched, reports the Daily. 

Also Read: Renowned plastic surgeon Dr Sam Chandra Bose passes away at 95

Powered by WPeMatico